The Encapsulation of Febuxostat into Emulsomes Strongly Enhances the Cytotoxic Potential of the Drug on HCT 116 Colon Cancer Cells

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Oct 14

PMID 33050567

Citations 15

Authors

Usama A Fahmy

Hibah M Aldawsari

Shaimaa M Badr-Eldin

Osama A A Ahmed

Nabil A Alhakamy

Helal H Alsulimani

Filippo Caraci

Giuseppe Caruso

Affiliations

Soon will be listed here.

Abstract

Febuxostat (FBX) is a drug able to inhibit xanthine oxidase and reduce uric acid production commonly used for the treatment of hyperuricemia in subjects suffering from gout. Several studies have also been directed at its use as anti-cancer drug during the last years, opening a window for its off-label use. In the present study, an optimized formulation in terms of vesicle size and drug release, obtained by encapsulation of FBX into the emulsomes (FBX-EMLs), was evaluated for its cytotoxic potential in human colorectal carcinoma (HCT 116) cells. The optimized FBX-EMLs formula had an improved half maximal inhibitory concentration (IC50), about 4-fold lower, compared to the free drug. The cell cycle analysis showed a significant inhibition of the HCT 116 cells proliferation following FBX-EMLs treatment compared to all the other conditions, with a higher number of cells accumulating on G2/M and pre-G1 phases, paralleled by a significant reduction of cells in G0/G1 and S phases. The optimized formula was also able to significantly increase the percentage of cell population in both early and late stages of apoptosis, characterized by a higher intracellular caspase-3 concentration, as well as percentage of necrotic cells. Lastly, the FBX ability to decrease the mitochondrial membrane potential was enhanced when the drug was delivered into the EMLs. In conclusion, the new formulation of FBX into EMLs improved all the parameters related to the anti-proliferative activity and the toxic potential of the drug towards colorectal cancer cells.

Citing Articles

Intranasal trimethyl chitosan-coated emulsomes containing tizanidine as brain-targeted therapy in spasticity: formulation, optimization, and pharmacokinetic assessment.

Elkomy M, Hendawy O, Zaki R, Tulbah A, Aldosari B, Ali A Drug Deliv Transl Res. 2024; .

PMID: 39666261 DOI: 10.1007/s13346-024-01753-0.

Andrographolide nanophytosomes exhibit enhanced cellular delivery and pro-apoptotic activities in HepG2 liver cancer cells.

Neamatallah T, Malebari A, Alamoudi A, Nazreen S, Alam M, Bin-Melaih H Drug Deliv. 2023; 30(1):2174209.

PMID: 36762548 PMC: 9930834. DOI: 10.1080/10717544.2023.2174209.

Metal Coordination and Biological Screening of a Schiff Base Derived from 8-Hydroxyquinoline and Benzothiazole.

Ribeiro N, Farinha P, Pinho J, Luiz H, Meszaros J, Galvao A Pharmaceutics. 2022; 14(12).

PMID: 36559078 PMC: 9785144. DOI: 10.3390/pharmaceutics14122583.

Atorvastatin-loaded emulsomes foam as a topical antifungal formulation.

Eita A, Makky A, Anter A, Khalil I Int J Pharm X. 2022; 4:100140.

PMID: 36465276 PMC: 9709243. DOI: 10.1016/j.ijpx.2022.100140.

Repurposing of atorvastatin emulsomes as a topical antifungal agent.

Eita A, Makky A, Anter A, Khalil I Drug Deliv. 2022; 29(1):3414-3431.

PMID: 36428290 PMC: 9707382. DOI: 10.1080/10717544.2022.2149898.

References

Alhakamy N, Badr-Eldin S, Ahmed O, Asfour H, Aldawsari H, Algandaby M . Piceatannol-Loaded Emulsomes Exhibit Enhanced Cytostatic and Apoptotic Activities in Colon Cancer Cells. Antioxidants (Basel). 2020; 9(5). PMC: 7278770. DOI: 10.3390/antiox9050419. View

Yu K . Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Pat Inflamm Allergy Drug Discov. 2008; 1(1):69-75. DOI: 10.2174/187221307779815020. View

Sung B, Prasad S, Yadav V, Aggarwal B . Cancer cell signaling pathways targeted by spice-derived nutraceuticals. Nutr Cancer. 2011; 64(2):173-97. PMC: 3645308. DOI: 10.1080/01635581.2012.630551. View

Hsiao K, Wu Y, Liu Z, Chuang C, Huang H, Kuo S . Anticancer Effects of Sinulariolide-Conjugated Hyaluronan Nanoparticles on Lung Adenocarcinoma Cells. Molecules. 2016; 21(3):297. PMC: 6274027. DOI: 10.3390/molecules21030297. View

Frampton J . Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. Drugs. 2015; 75(4):427-38. DOI: 10.1007/s40265-015-0360-7. View

Van der Jeught K, Xu H, Li Y, Lu X, Ji G . Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018; 24(34):3834-3848. PMC: 6141340. DOI: 10.3748/wjg.v24.i34.3834. View

Mahajna S, Kadan S, Tietel Z, Saad B, Khasib S, Tumeh A . In Vitro Evaluation of Chemically Analyzed Extract Efficacy in Apoptosis Induction and Cell Cycle Arrest of the HCT-116 Colon Cancer Cell Line. Molecules. 2019; 24(22). PMC: 6891740. DOI: 10.3390/molecules24224139. View

McKenney J . Pharmacologic characteristics of statins. Clin Cardiol. 2003; 26(4 Suppl 3):III32-8. PMC: 6654766. DOI: 10.1002/clc.4960261507. View

Kalaydina R, Bajwa K, Qorri B, DeCarlo A, Szewczuk M . Recent advances in "smart" delivery systems for extended drug release in cancer therapy. Int J Nanomedicine. 2018; 13:4727-4745. PMC: 6108334. DOI: 10.2147/IJN.S168053. View

10.

Song I, Kim H, Lee S, Jeong S, Kim N, Ko K . Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells. Int J Cancer. 2013; 133(6):1357-67. DOI: 10.1002/ijc.28149. View

11.

Uzu M, Nonaka M, Miyano K, Sato H, Kurebayashi N, Yanagihara K . A novel strategy for treatment of cancer cachexia targeting xanthine oxidase in the brain. J Pharmacol Sci. 2019; 140(1):109-112. DOI: 10.1016/j.jphs.2019.04.005. View

12.

Bisht M, Bist S . Febuxostat: a novel agent for management of hyperuricemia in gout. Indian J Pharm Sci. 2012; 73(6):597-600. PMC: 3480742. DOI: 10.4103/0250-474X.100231. View

13.

Mukthinuthalapati M, Bandaru S, Bukkapatnam V, Mohapatro C . Development and validation of a stability-indicating RP-HPLC method for the determination of febuxostat (a xanthine oxidase inhibitor). J Chromatogr Sci. 2012; 51(10):931-8. DOI: 10.1093/chromsci/bms192. View

14.

Ucisik M, Sleytr U, Schuster B . Emulsomes meet S-layer proteins: an emerging targeted drug delivery system. Curr Pharm Biotechnol. 2015; 16(4):392-405. PMC: 4460288. DOI: 10.2174/138920101604150218112656. View

15.

Alfaifi M, Shati A, Elbehairi S, Fahmy U, Alhakamy N, Md S . Anti-tumor effect of PEG-coated PLGA nanoparticles of febuxostat on A549 non-small cell lung cancer cells. 3 Biotech. 2020; 10(3):133. PMC: 7036082. DOI: 10.1007/s13205-020-2077-x. View

16.

Karimi P, Islami F, Anandasabapathy S, Freedman N, Kamangar F . Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014; 23(5):700-13. PMC: 4019373. DOI: 10.1158/1055-9965.EPI-13-1057. View

17.

Awan Z, Fahmy U, Badr-Eldin S, Ibrahim T, Asfour H, Al-Rabia M . RETRACTED: Awan et al. The Enhanced Cytotoxic and Pro-Apoptotic Effects of Optimized Simvastatin-Loaded Emulsomes on MCF-7 Breast Cancer Cells. 2020, , 597. Pharmaceutics. 2024; 16(2). PMC: 10893105. DOI: 10.3390/pharmaceutics16020191. View

18.

Johnson C, Wei C, Ensor J, Smolenski D, Amos C, Levin B . Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013; 24(6):1207-22. PMC: 4161278. DOI: 10.1007/s10552-013-0201-5. View

19.

Tamura K, Kawai Y, Kiguchi T, Okamoto M, Kaneko M, Maemondo M . Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol. 2016; 21(5):996-1003. DOI: 10.1007/s10147-016-0971-3. View

20.

Caruso G, Distefano D, Parlascino P, Fresta C, Lazzarino G, Lunte S . Receptor-mediated toxicity of human amylin fragment aggregated by short- and long-term incubations with copper ions. Mol Cell Biochem. 2016; 425(1-2):85-93. DOI: 10.1007/s11010-016-2864-1. View